Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of givinostat
NCT04821063Phase 1Completed
- Sponsor
- Italfarmaco
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of givinostat in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and polycythemia vera (PV) (4 arms), sponsored by Italfarmaco. Primary endpoint: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval at 36 hours. Started Apr 2021; status: completed.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04821063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821063.